objectives To assess the relationship between CD4 count at presentation and ART uptake and assess predictors of timely treatment initiation in rural KwaZulu-Natal, South Africa. results A total of 4739 patients presented for care with eligible CD4 counts. The proportion initiating ART within six months of diagnosis was 67% (95% CI 63, 71) in patients with CD4 ≤ 50, 59% (0.55, 0.63) in patients with CD4 151-200 and 48% (95% CI 44, 51) in patients with CD4 301-350. The hazard of starting ART fell by 17% (95% CI 14, 20) for every 100-cell increase in baseline CD4 count. Among healthier patients under demographic surveillance (n = 193), observable sociodemographic, economic and geographic predictors did not add discriminatory power beyond CD4 count, age and sex to identify patients at high risk of non-initiation.
Introduction
2015 World Health Organization (WHO) guidelines recommend HIV treatment for all HIV-infected individuals regardless of CD4 count [1] . There are substantial benefits to early antiretroviral therapy (ART) initiation both for the patient's own health and for public health, as a result of the reduced transmission risk by patients with undetectable viral loads [2] [3] [4] [5] [6] [7] . However, to reach the high levels of ART coverage targeted by UNAIDS [8] , large numbers of asymptomatic patients with high CD4 counts who were previously ineligible for ART must now accept and initiate treatment. If asymptomatic patients do not initiate ART, the full benefits of treatment as prevention will not be realised.
There is growing evidence of patients failing to initiate ART, even though they have linked to care and have been identified as eligible for treatment initiation [9] [10] [11] [12] [13] . One reason proposed is that many patients believe they are 'too healthy' to require ART. Previous studies have reported mixed results regarding the effect of health status on ART initiation. Some have found that healthier individuals are less likely to initiate treatment [14] , and others have found that individuals presenting with advanced disease are more likely to die or be lost to follow-up before ART initiation [15, 16] . These mixed findings may reflect heterogeneity across different settings and data limitations of standard clinical cohorts, which typically enrol patients at ART initiation, not at HIV testing. It is also possible that the relationship between health and ART uptake is nonmonotonic: patients who are 'too healthy' opt out of treatment, while those who are 'too sick' may not survive long enough to start. Beyond health status at presentation, studies have suggested that age [17] , gender [15, 17] , distance to clinic [18] [19] [20] , living in rural areas [21] , competing childcare obligations [22] , education levels [12, 23] , financial security [18, 24] and difficulty finding time off from work [16] may also influence uptake.
To better understand failure to initiate ART, we assessed predictors of ART uptake in rural South Africa. Using data on all patients diagnosed with HIV in the public sector HIV Treatment and Care Programme in Hlabisa Sub-District, KwaZulu-Natal, we tested the hypothesis that among patients with ART-eligible CD4 counts (CD4 ≤ 350), those with higher CD4 counts were less likely to initiate treatment. Exploiting the unique opportunity to link a subset of the clinical cohort to a population-based demographic and health surveillance system, we also examined a range of sociodemographic, economic and geographic predictors of failure to initiate ART to guide targeting of future interventions.
Methods

Ethics
Ethical approval for data collection, linkage and analysis by the Africa Health Research Institute (AHRI) was obtained from the University of KwaZulu-Natal Biomedical Research Ethics Committee. Verbal informed consent was obtained from household respondents. The analyses conducted for this study consisted of secondary analysis of de-identified data and were determined 'not human subjects research' by the Boston University Medical Campus IRB.
Data and study population
The Hlabisa HIV Treatment and Care Programme provides public sector HIV care at 17 primary health clinics (PHCs) and one subdistrict hospital in Hlabisa sub-district in rural KwaZulu-Natal province. The programme was supported by the US President's Emergency Programme for AIDS Relief during the period of study [25] . From 2004 through the end of 2013, clinical records were captured systematically in a database supported by the Africa Health Research Institute (formerly known as the Africa Centre for Population Health), which maintains a demographic and health surveillance system in the area. The cohort is extensively described elsewhere [25] and was one of the few clinical cohorts in sub-Saharan Africa to enrol patients at their first recorded CD4 count, usually performed at the time of HIV diagnosis, rather than at ART initiation. Patients eligible for ART attended three treatment literacy and counselling sessions prior to starting therapy. They were required to identify a treatment supporter and to sign an agreement to adhere before starting [25] .
Since 2000, the Africa Health Research Institute has collected longitudinal sociodemographic data through semiannual household survey visits, with response rates of >99 per cent [26] , on a cohort of more than 100 000 people living in a 167-square-mile demographic surveillance area in northern KwaZulu-Natal. Socio-economic and health information are included in the surveys annually; all households are geocoded and distances to nearest clinics have been calculated. About 40% of the Hlabisa HIV Treatment and Care Programme catchment area population reside in the surveillance area. Clinical records have been linked at the individual level with the demographic surveillance using national identification numbers, full name, age and sex [27, 28] .
The study population included all adults (≥18 years old) who received their first CD4 count between 11 August 2011 and 31 December 2012 in the Hlabisa HIV Treatment and Care Programme and were eligible for ART under public sector guidelines (CD4 count ≤350). Patients who first presented for HIV care at the Hlabisa sub-district hospital or at mobile sites, rather than the PHCs in the programme, were excluded, as were those whose age or gender could not be determined.
Outcome measures
The outcome of interest was the length of time from the date of an individual's first recorded CD4 count to the date that person initiated ART or end of follow-up. The analysis was restricted to patients whose first recorded CD4 count was ≤350 cells and thus eligible for ART. ART initiation data were collected until 31 December 2013, providing each individual in our study cohort with at least 12 months to initiate ART. Person-time was included from the date of an individual's first recorded CD4 count until the date that person initiated ART, died or reached the end of the study period on 31 December 2013. For analysis of the population residing in the surveillance area, person-time was further censored when individuals moved away from their baseline place of residence.
Predictors of ART initiation
First recorded CD4 count (cells/mm 3 ), age (years) and sex were determined from the clinical database and available for the full study population. For the subsample of patients residing within the surveillance area, we additionally extracted data on a range of sociodemographic, economic and geographic characteristics that were potential predictors of ART uptake. We included data on the distance from an individual's residence to the nearest clinic (coded as 0-2 km or >2 km), and whether the residence was located in a rural or urban/peri-urban area. Using data from the demographic surveillance, we assessed whether there was at least one child under six in the household and whether at least one other household member had previously linked to HIV care. Socio-economic characteristics were assessed in the survey wave closest to the date of first CD4 count. Education was measured as the number of years of education received (1-15 years). We categorised patients as employed if they were employed or earning any income. Finally, using a principal component analysis of the responses from 53 survey questions regarding household assets, we identified the 10 assets most strongly correlated with the first principal component and measured household wealth as a count of how many of those assets the household possessed. We imputed education and household wealth for patients with missing data using the mean of the available sample. Dummy variables indicating observations with imputed values were included as controls during analysis.
Analytical approach
To determine whether there was an association between patient health and the probability of starting treatment, we used survival analysis to assess the length of time from the date of an individual's first recorded CD4 count to the date that person initiated ART, stratified by baseline CD4 count. We produced Kaplan-Meier estimates of the likelihood of ART initiation within 6 months for each 50-cell CD4 count category. We repeated the analysis additionally stratifying by gender.
We then assessed the association between first CD4 count and the hazard of initiating ART using Cox proportional hazards models. We first estimated crude hazard ratios with CD4 counts alone. To assess whether the relationship between first CD4 count and initiation was confounded by other observable factors, we adjusted the model for age and sex, and in a third model, for age, sex, age-sex interactions, the year of the patient's first recorded CD4 count, and the clinic where the patient was registered. These covariates represent all baseline data available for the full Hlabisa sample on the date of patients' first CD4 counts. For each of these three covariate specifications, we modelled CD4 counts as a series of 50-cell CD4 categories and separately as a continuous predictor scaled so that a unit increase represents 100 cells/mm 3 . To identify persons most at risk of not initiating ART, we used Cox proportional hazards models to assess predictors of the initiation hazard for the subsample residing within the surveillance area. Due to the reduction in sample size, we included CD4 cell count as a continuous predictor to preserve power. We estimated three predictive models, which were nested to evaluate whether the addition of covariates increased predictive power. We started with first CD4 count alone and then added age, sex and age*sex (the 'age-sex-CD4' model). Lastly, we included all socio-economic and geographic predictors described above to assess whether additional information on factors thought to influence uptake of ART but not regularly collected in clinical databases predicted non-initiation in our sample (the 'all predictors' model). To assess whether the predictors were jointly significant, we conducted an F-test on the joint null hypothesis test that the coefficients on all socio-economic and geographic predictors were equal to zero. We repeated this analysis for the subpopulation under demographic surveillance with a first recorded CD4 count between 201 and 350 cells to explore whether predictors of initiation differed among healthier patients, a population targeted in current interventions.
Some patients may have died or out-migrated before they had the opportunity to initiate ART. Although the rate of death and out-migration is low in the six-month window following clinical presentation which is the focus of our analysis, our results could be affected by coding these patients as having not initiated. To assess the robustness of our results, we considered death and outmigration as competing risks in our predictive regression model for the ACDIS cohort, censoring follow-up time at dates of death and/or out-migration.
Finally, we assessed the performance of the predictive models in identifying people at greatest risk of non-initiation. Specifically, we assessed whether the predicted probability of non-initiation would provide a useful 'risk score' and evaluated whether a threshold rule on such a score would help identify patients to be targeted for future interventions to increase ART uptake. We used logistic models to predict the probability of ART initiation within six months for each patient under the 'agesex-CD4' model and under a series of adjusted models where we added socio-economic and geographic predictors individually to the 'age-sex-CD4' model based on what was found to be significant in the previous analysis. We then created indicators to identify patients at 'high risk' for not starting ART, experimenting with thresholds set to target the 20%, 40%, 60% and 80% highest risk patients. For each threshold, we calculated the proportion of all true non-initiators identified as 'high risk' by the risk score. We used repeated random sampling cross-validation techniques to prevent overfitting and estimate confidence intervals (described in Appendix Table 4 ). In assessing performance of our risk score, we note that a high-performing risk score would enable identification of a small group of 'high risk' patients representing a large proportion of the patients who in fact would fail to initiate ART. We compared the results across different models to assess the benefit of including sociodemographic, economic and geographic predictors in our model, in addition to CD4, age and sex.
Results Table 1 presents descriptive statistics for the full sample, the subpopulation of patients residing within the surveillance area, and for healthier patients residing in the surveillance area (200 < CD4 ≤ 350). Of the 4630 *Those who were censored were given an infinitely large value for days taken to initiate ART.
patients presenting for care between 2011 and 2012 with eligible CD4 counts, 2786 (60%) initiated ART within the study period, of whom 2626 (57%) and 2730 (59%) initiated within 6 months and 1 year of their first recorded CD4 count, respectively. Thirty-seven patients were excluded because either their age or gender was not reported. Among those who initiated ART, over 95% of patients did so at the same clinic where they received their first CD4 count, rather than at one of the other 16 clinics in the area, suggesting a fair amount of stability in the six-month follow-up period (Appendix Table 5 ). Of the 434 patients residing within the surveillance area, 320 (74%) initiated ART within the study period, of whom 300 (69%) and 312 (72%) initiated within 6 months and 1 year of their first recorded CD4 count. These rates were lower in the healthier subset of patients (n = 193), of whom 113 (59%) and 121 (63%) initiated ART within 6 months and 1 year, respectively. Figure 1 shows the Kaplan-Meier likelihood of initiating ART within 6 months by first recorded CD4 count. While the sickest individuals (CD4 ≤ 50) had a 67% (95% CI 63, 71) chance of initiating ART within 6 months, the probability of initiating ART decreased approximately linearly by an average of 3 percentage points for every 50-cell count increase. 48% (95% CI 44, 51) of patients with first CD4 counts 301-350 initiated ART (Appendix Table 1 ). These trends did not differ by sex (Appendix Figure 1) . Table 2 presents hazard ratios of ART initiation associated with each predictor in the full sample. The hazard of ART initiation fell by 17% (95% CI 14, 20) for every 100-cell increase in baseline CD4 count, with CD4 count modelled continuously. These effects were robust to alternate specifications controlling for age, sex, age-sex interactions, year of first recorded CD4 count and clinic fixed effects. Conditional on other covariates, rates of ART initiation were lowest among younger patients. No differences were observed by sex. Table 3 presents hazard ratios of ART initiation associated with predictors in the subpopulation of residents within the surveillance area and in surveillance residents with higher CD4 counts. In the all-CD4 count sample, patients with higher CD4 counts were less likely to initiate ART. The initiation hazard fell by 25% (95% CI 0.68-0.84) for every 100-cell increase in CD4 count. After adjusting for age, sex, first recorded CD4 cell count and age-sex interactions, we identified predictors of noninitiation including living over 2 km away from the nearest clinic (HR 0.80, 95% CI 0.64-0.998), living in a rural area (HR 0.77, 95% CI 0.62-0.96) and having children under the age of 6 (HR 0.74, 95% CI 0.56-0.97).
In the healthier subpopulation, none of the predictors had a statistically significant association with ART initiation in either the crude, adjusted or fully mutually adjusted models. However, effect sizes for distance to clinic, rural and children under 6 were similar to those observed in the full resident population. Considering death and out-migration as competing risks did not substantially change the results (Appendix Table 6 ).
Using a logistic model (Appendix Table 3 ), we estimated the probability of ART initiation within 6 months for each patient under the 'age-sex-CD4' model and 'all predictors' model and assessed the distribution of predicted probabilities by actual initiation status (Appendix Figure 2) . As expected, predicted probabilities of non-initiation are higher among those who in fact did not initiate (termed 'true non-initiators' below). Figure 1 Kaplan-Meier probability of ART initiation within 6 months by earliest CD4 count. Note: Kaplan-Meier curves were constructed for time to ART initiation, separately by 50-cell CD4 count bin. Each data point presents the probability of having initiated ART within six months from date of first CD4 count. Asymptotic 95% confidence intervals are reported. Sex-stratified estimates and numerical values are presented in Appendix Table 1 and Appendix Figure 1 . *P < 0.05, **P < 0.01, ***P < 0.001. †Model includes indicator variables for year of earliest CD4 cell count and earliest registration clinic. Coefficients on these predictors are suppressed. geographic variables that were significant predictors in the previous analysis (number of children under 6, distance to the nearest clinic, rural). We report the per cent of true non-initiators identified if 20%, 40%, 60% or 80% of patients were determined to be 'high risk' for non-initiation. Targeting interventions to increase ART uptake on the basis of age, sex and first CD4 count would substantially improve targeting over an intervention allocated at random (the 45-degree line). However, screening for potential non-initiators using a wide range of socio-economic and geographic predictors did not outperform the simple screening tool using age, sex and CD4 count. In general, discriminatory power was rather low. 40% of all patients would have to be targeted with an intervention to reach 58% of would-be non-initiators. 80% of all patients would have to be targeted to reach 90% of non-initiators.
Discussion
Treating all persons infected with HIV regardless of CD4 count is likely our best way to reduce morbidity and mortality and to curtail the spread of HIV. Yet, uptake of ART among patients diagnosed with HIV and eligible for ART is far from universal. In a large prospective cohort in rural South Africa, we found that only 57% of patients with an eligible CD4 count (≤350) initiated ART within six months, in spite of treatment being available for free at point of service. Why do patients not initiate ART? Within the population that was eligible for ART at a threshold of 350 CD4 cells/mm 3 , healthier patients were much less likely to initiate ART than patients presenting with low CD4 counts. Initiation probabilities fell from 67% (CD4 0-50 cells/mm covariates. This is some of the first quantitative evidence on the association between CD4 count at presentation and ART uptake [13] [14] [15] [16] , confirming evidence in qualitative studies [29] .
Reasons for failing to initiate treatment have been identified on both the patient and the provider sides. On the provider side, multiple required visits, long waiting times, stock-outs of supplies, staff absences and poor communication between staff and patients all deter treatment initiation [9, [30] [31] [32] . Patients themselves face barriers ranging from stigma and fear of disclosure to the costs of clinic visits and the risk of wage loss [29, 30, 33] . In quantitative studies, variables associated with failing to start treatment include age [17] , gender [15, 17] , distance to clinic [18] [19] [20] , living in rural areas [21] , competing childcare obligations [22] , education levels [12, 23] , financial security [18, 24] and difficulty finding time off from work [16] . Feeling healthy may both reinforce a patient's other reasons for avoiding initiation and constitute a reason in itself.
A number of approaches to increase ART uptake among eligible patients have shown promise [34] . In a randomised trial in Johannesburg, South Africa, initiating patients on ART on the same day as HIV diagnosis Table 4 .
sharply reduced loss to follow-up before ART initiation and led to an overall increase in viral suppression among patients eligible for treatment [35] . Trials in Uganda [36] , China [37] and the United States [38] , all found that simplifying the process of treatment initiation improves ART uptake. Improved counselling was associated with very high uptake in Cape Town, South Africa, in a pilot project [39] . Other potentially effective approaches include financial incentives to remain in care [40] , active tracing of patients who do not return to start ART and homebased treatment initiation [41] . The challenge for national HIV programmes will be to allocate resources to encourage relatively healthy HIV patients to initiate ART without diminishing investment in those with low CD4 counts who must start treatment immediately. We found that first eligible CD4 count was the most valuable predictor of ART non-initiation. Nevertheless, reallocating resources towards patients with high CD4 counts could crowd out sicker patients to the detriment of overall health outcomes [42] . To avoid such unintended consequences, health systems have prioritised the sickest patients for faster initiation [43] . Ideally, patients at risk of non-initiation and who might benefit from interventions could be targeted in advance. However, beyond CD4 count, age and sex, neither commonly available clinical variables nor socio-economic and geographic characteristics thought to influence uptake had any effect at all on our ability to identify high-risk patients.
Our study had several limitations. First, the size of the subpopulation residing in the demographic surveillance and seeking care with CD4 counts between 200 and 350 cells was only n = 193. This small population size limited our power to detect statistically significant socio-economic predictors of non-initiation. On the other hand, the point estimates did not suggest very large effects, and including additional variables beyond CD4, age and sex did not increase the discriminatory power of the predictive model to identify patients at high risk of failure to initiate ART. Second, ART uptake was in general higher among residents of the population surveillance area compared to the full Hlabisa Cohort. One explanation is that this analysis was limited to residents, whereas the full Hlabisa cohort may have included patients passing through and not residing in the catchment area. It is also possible that the AHRI's continuous demographic surveillance and community health education efforts led to higher uptake. In any case, the generalisability of our predictive models may be limited. Third, it is possible that we are underestimating ART uptake due to private sector care-seeking and out-migration to other health catchment areas. However, private sector utilisation for ART is low in this setting, and out-migration is unlikely to be a major factor in a six-month initiation window. Fourth, the patients in our sample were limited to those who were eligible for ART under earlier guidelines. It is possible that the results we report will not apply to patients with CD4 counts above 350, who are all now eligible for ART under September 2016 revisions to South Africa's national guidelines. Finally, some patients -particularly those presenting with low CD4 counts -may have died before they had the opportunity to start ART. Our analysis coded these patients (accurately) as having not started ART. Treating death and out-migration as competing risks for ART initiation yielded similar results. This was confirmed in analysis of the ACDIS subsample, where death and out-migration could be reliably estimated.
If healthier patients are significantly less likely to start ART than sicker patients, implementation of WHO recommendations to offer ART to all patients at HIV diagnosis may have less impact than policy-makers have hoped [44] . Our results suggest that increasing treatment coverage to levels necessary to stop HIV transmission may be more difficult than has been reflected in models of 'test and treat' [45, 46] . Success will depend not just on expanding treatment eligibility to asymptomatic patients [47] but also on rethinking how care is provided to healthy patients and how to increase demand for early ART. We have shown that targeting initiation support interventions based on easily collected socio-economic and geographic factors is unlikely to be a solution. CD4 count remains highly predictive and potentially could be used to stratify care from diagnosis until patients are established on ART. Further research to better understand how to increase initiation among patients with high CD4 counts -in real-world clinical settings and at scale -is critical to achieving the reductions in transmission necessary to bring about the end of the epidemic.
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